Latest Regulatory Engagement News

Neurizon Therapeutics has commenced dosing in a major Phase 2/3 trial of its lead drug NUZ-001 for ALS, marking a critical step in advancing treatment options for this devastating disease.

Atlas Arteria reports a 39% drop in net profit for 2025, hit by French tax changes, yet maintains its distribution guidance amid traffic growth and strategic leadership shifts.

Critical Resources Limited highlights significant progress in its lithium and gold projects across Canada and New Zealand, alongside pioneering work in next-generation solid-state lithium-ion batteries.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

BlinkLab Limited reported a $3.76 million loss for H1 FY2026 as it progresses pivotal clinical studies for its digital autism and ADHD diagnostic tools, expanding its U.S. and European trial networks and engaging closely with the FDA.

Horizon Oil Limited reported a 26% rise in production and a stable EBITDAX despite a 15% drop in oil prices, driven by its recent Thailand asset acquisition. The company declared an interim dividend of AUD 1.5 cents per share, signalling confidence in its cash flow and growth strategy.

Immutep Limited reported a doubling of its half-year loss to A$44.9 million amid expanded clinical trial activity and secured a USD 20 million upfront payment from a strategic licensing deal with Dr. Reddy’s Laboratories.

Besra Gold has obtained conditional renewal of a crucial mining lease at its Bau Gold Project, securing tenure over the Jugan deposit and paving the way for further project development.

Greenwing Resources has significantly enhanced the economics of its Que River Project following a sharp rise in key metal prices, nearly doubling projected cash flows and advancing a two-stage development plan.

Australian Vanadium Limited has broadened its Optimised Feasibility Study to include high purity vanadium products aimed at aerospace, defence, and advanced manufacturing sectors, aligning with evolving critical minerals demand without delaying project timelines.